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All these estimates are necessarily unprecise, being based on
small numbers. They could be used in connection with specula-
tions regarding the critical age at first use, arguing that a very high
ratio between OR* and OR is unlikely, thus making age 18 years
an appealing choice.
Finally, we do not completely agree with DrTomasson when he
claims that the two Icelandic studies and the results of the
Collaborative Group on Hormonal Factors in Breast Cancer
(1996) all show that use ofOC has very little impact on the risk for
breast cancer. We feel that there is still aquestion mark concerning
the effects ofOC use atyoung age. Our study, as well as the one by
the Collaborative Group give rise to some concern about this
matter. The study of the Collaborative Group also found an
increased risk in young users and, to quote the paper, 'The avail-
able data for use beginning before age 20 indicate that there is no
substantial increase of breast cancer risk in this subgroup more
than 5 years after cessation of use, but virtually all the existing
information relates to women younger than 45. In the next decade
women who began use as teenagers will reach their late 40s and
early 50s, when breast cancer is more common. When the new
data on the long-term effects ofearly use become available it will
be necessary to re-examine the worldwide evidence'.
L Tryggvadottir, H Tulinius and GB Gudmundsdottir
Epidemiological Unit, kcelandic CancerRegistry,
kcelandic Cancer Society, PO Box 5420, 1S-125Reykjavik, kceland
REFERENCES
Ambrosone CB, Freudenheim JL, Graham S, Marshall JR, Vena JE, Brasure JR,
Michalek AM, Laughin R, Nemoto T, Gillenwater KA, Harrington AM and
Shields PG (1996) Cigarette smoking, N-acetyltransferase 2 genetic
polymorphisms, and breast cancer risk. JAMA 276: 1494-1501
Collaborative Group on Hormonal Factors in Breast Cancer (1996) Breast cancer
and hormonal contraceptives: collaborative reanalysis ofindividual data on
53,297 women with breast cancer and 100,239 women without breast cancer
from 54 epidemiological studies. Lancet347: 1713-1727
T6masson H and T6masson K (1996) Oral contraceptives and risk ofbreast cancer.
A historical prospective case-control study. Acta Obstet Gynecol Scand 75:
157-161
Tryggvad6ttir L, Tulinius H and Gudmundsd6ttir GB (1997) Oral contraceptive use
at a young age and the risk ofbreast cancer. An Icelandic, population-based
cohort study ofthe effect ofbirth year. BrJCancer 75: 139-143
How best,to express oestrogen receptor activity
Sir
With reference to the recenteditorial by RA Hawkins (1996), I feel
compelled to take issue with the opening sentence and the rather
provocative statement 'The oestrogen receptor (ER), discovered
around 1960 ...' and the references cited therein. Whatever the
controversy surrounding methods ofassay and the clinical signifi-
cance of ER as a prognostic and predictive factor, its nascent
details are worthy ofclarification.
The physiological basis for responses to early forms of ablative
endocrine therapies was unknown atthe time oftheir clinical intro-
duction (Schinzinger, 1889; Beatson, 1896). Oestrogens were only
isolated in crystalline form in 1936 from sows' ovaries by
MacCorquadale and co-workers (1936). Despite the isolation of
oestrogens and animal data implicating these substances in both
initiation and promotion of mammary tumours in rodents (Eisen,
1932; Lacassagne, 1932), evidence for a direct role in normal
breast function and development of mammary neoplasia was
lacking. Glascock and Hoekstra published a seminal paper in 1959
on the selective accumulation ofradiolabelled synthetic oestrogens
in target organs that respond to these hormones. A tritiated
oestrogen derivative of high specific activity selectively localized
in the mammary glands, uterus, vagina and pituitary glands
of immature goats and sheep. This was important corroborative
data linking oestrogen with normal breast physiology, and subse-
quently the selective uptake ofradiolabelled systemic oestradiol by
7,12-dimethylbenzanthracene (DMBA)-induced rat mammary
tumours was demonstrated (King, 1965; Mobbs, 1966; Terenius,
1968). However, although the existence of putative oestrogen
receptors was postulated they were not identified in these experi-
ments.
The formal discovery of the oestrogen receptor (ER) came in
the mid to late 1960s by groups ledby Gorski and Jensen (Toft and
Gorski, 1966; Jensen et al, 1968). These workers carried out
further experiments that consolidated understanding ofoestrogen-
stimulated growth. Radiolabelled oestradiol incubated with uterine
tissue of immature rats was bound to cytosolic and nuclear frac-
tions. The oestradiol in the cytosol was associated with a specific
oestrogen-binding protein that was undetectable in the nuclear
fraction. These findings led to formulation of an early model for
oestrogen-mediated events in which oestrogen interacted directly
with target cells via cytoplasmic receptors. Subsequent transloca-
tion of the ligand-receptor complex to the nucleus was followed
by interaction with DNA and modulation of gene transcription.
The presence or absence of ER was consistent with data showing
that uptake of tritiated oestradiol by breast tumour samples was
essentially 'all or none' - tumours accumulated oestradiol either
significantly orhardly atall. This preliminary model has now been
refined and, in particular, evidence now suggests that native forms
of the unoccupied ER do reside within the nucleus. The precise
conditions that determine nuclear localization remain to be eluci-
dated (Jensen, 1991).
These observations have heralded the modern era of endocrine
therapy in which the clinical response of advanced breast cancers
could be predicted from the ER content of metastatic lesions
(McGuire, 1975) and later of primary tumours (Campbell, 1981).
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Science is an evolutionary process, and contemporary scientific
debate should not eclipse nor distort historical fact.
JR Benson,
Department ofSurgery Westminster Ward,
Level 3, Chelsea and Westminster Hospital,
369 Fulham Road, London SWIO 9NH, UK
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